A Phase 1 interventional study of AHLeveeS System in Overactive Bladder, sponsored by Neuspera Medical, Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by Neuspera Medical, Inc. · Phase 1, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Urinary Bladder, Overactive with a site in Netherlands — none open to participants now, 1 under way, none of them phase 3. Urinary Bladder, Overactive · Netherlands.
Among the 43 studies in Urinary Bladder, Overactive with a site in Netherlands, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 1, and was the 39th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →None of the 43 studies in Urinary Bladder, Overactive with a site in Netherlands is open now. The open studies under Urinary Bladder, Overactive, anywhere →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 70 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 234 across the 36 interventional studies, 100 across the 7 observational. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Neuspera Medical, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Neuspera Medical, Inc. has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Urinary Bladder, Overactive with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: AHLeveeS System
AHLeveeS System for treatment of overactive bladder
Sacral Nerve Response measured by observed bellow response and big toe flexion
Stimulation of the S3 sacral nerve measured by observed bellows response and big toe flexion
Time frame: Procedure
AHLeveeS System placement in the S3 foramen assessed by fluoroscopy image
Confirm that the AHLeveeS System can be correctly placed and inserted in close proximity of the sacral nerve in the S3 foramina assessed by fluoroscopy image
Time frame: Procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Nov 2017, 2 months.
Of 20 industry-sponsored phase 1 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 30 studies reached it within 9 months; a quarter within 4 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuspera Medical, Inc.